Effects of a foot pump on the incidence of deep vein thrombosis after total knee arthroplasty in patients given edoxaban:A randomized controlled study

Medicine (United States)

Volumn 95, Issue 1, 2016, Pages

  Sakai, Tatsuya ^a,b   Izumi, Masahiro ^a,b   Kumagai, Kenji ^a,b   Kidera, Kenichi ^a,b   Yamaguchi, Takayuki ^a,b   Asahara, Tomohiko ^a,b   Kozuru, Hideko ^a,b   Jiuchi, Yuka ^a,b   Mawatari, Masaaki ^a,b   Osaki, Makoto ^a,b   Motokawa, Satoru ^a,b   Migita, Kiyoshi ^a,b  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; EDOXABAN; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; ARTICLE; COMPRESSION INSTRUMENT; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DRUG SAFETY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INCIDENCE; INFORMED CONSENT; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TOTAL KNEE REPLACEMENT; VEIN THROMBOSIS; AGE; BODY MASS; JAPAN; KNEE REPLACEMENT; PHYSIOTHERAPY; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; REHABILITATION; SEX DIFFERENCE; VENOUS THROMBOSIS; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; BODY MASS INDEX; FEMALE; HUMANS; INCIDENCE; JAPAN; MALE; PHYSICAL THERAPY MODALITIES; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; PYRIDINES; SEX FACTORS; THIAZOLES; VENOUS THROMBOSIS;

EID: 84955305201     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002247     Document Type: Article

References (39)

1. Ethgen O, Bruyère O, Richy F, et al. Health-related quality of life in total hip and total knee arthroplasty A qualitative and systematic review of the literature. J Bone Joint Surg Am. (86-A):2004:963-974.
2. Kanchanabat B, Stapanavatr W, Meknavin S, et al. Systematic review and meta-analysis on the rate of postoperative venous thromboembolism in orthopaedic surgery in Asian patients without thromboprophylaxis. Br J Surg. 2011;98:1356-1364.
3. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):381S-453S.
4. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e278S-e325S.
5. Lieberman JR, Pensak MJ. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2013;95:1801-1811.
6. Lachiewicz PF. Comparison of ACCP and AAOS guidelines for VTE prophylaxis after total hip and total knee arthroplasty. Orthopedics. 2009;32:74-78.
7. Blanchard J, Meuwly JY, Leyvraz PF, et al. Prevention of deep-vein thrombosis after total knee replacement Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br. 1999;81:654-659.
8. Westrich GH, Sculco TP. Prophylaxis against deep venous thrombosis after total knee arthroplasty Pneumatic plantar compression and aspirin compared with aspirin alone. J Bone Joint Surg Am. 1996;78: 826-834.
9. Kakkos SK, Warwick D, Nicolaides AN, et al. Combined (mechanical and pharmacological) modalities for the prevention of venous thromboembolism in joint replacement surgery. J Bone Joint Surg Br. 2012;94:729-734.
10. Fuji T, Fujita S, Tachibana S, et al. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010;8:2458-2468.
11. Fuji T, Fujita S, Kawai Y, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res. 2014;133:1016-1022.
12. Kory PD, Pellecchia CM, Shiloh AL, et al. Accuracy of ultrasono-graphy performed by critical care physicians for the diagnosis of DVT. Chest. 2011;139:538-542.
13. Schwarz T, Schmidt B, Schmidt B, et al. Interobserver agreement of complete compression ultrasound for clinically suspected deep vein thrombosis. Clin Appl Thromb Hemost. 2002;8:45-49.
14. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost. 2010;8:504-512.
15. Schiff RL, Kahn SR, Shrier I, et al. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophy-laxis. Chest. 2005;128:3364-3371.
16. Choi BY, Huo MH. Venous thromboembolism following total knee replacement. J Surg Orthop Adv. 2007;16:31-35.
17. White RH, Henderson MC. Risk factors for venous thromboembo-lism after total hip and knee replacement surgery. Curr Opin Pulm Med. 2002;8:365-371.
18. Lewis CG, Inneh IA, Schutzer SF, et al. Evaluation of the first-generation AAOS clinical guidelines on the prophylaxis of venous thromboembolic events in patients undergoing total joint arthro-plasty: experience with 3289 patients from a single institution. J Bone Joint Surg Am. 2014;96:1327-1332.
19. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833-1840.
20. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786.
21. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594-604.
22. Kakkos SK, Caprini JA, Geroulakos G, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev. 2008;4:CD005258.
23. Warwick D, Harrison J, Glew D, et al. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement A prospective, randomized trial. J Bone Joint Surg Am. 1998;80:1158-1166.
24. Wheeler HB, Hirsh J, Wells P, et al. Diagnostic tests for deep vein thrombosis. Clinical usefulness depends on probability of disease Arch Intern Med. 1994;154:1921-1928.
25. Colwell CW Jr, Froimson MI, Anseth SD, et al. A mobile compression device for thrombosis prevention in hip and knee arthroplasty. J Bone Joint Surg Am. 2014;96:177-183.
26. Fujisawa M, Naito M, Asayama I, et al. Effect of calf-thigh intermittent pneumatic compression device after total hip arthroplasty: comparative analysis with plantar compression on the effectiveness of reducing thrombogenesis and leg swelling. J Orthop Sci. 2003;8:807-811.
27. Pitto RP, Hamer H, Heiss-Dunlop W, et al. Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. J Bone Joint Surg Br. 2004;86:639-642.
28. He ML, Xiao ZM, Lei M, et al. Continuous passive motion for preventing venous thromboembolism after total knee arthroplasty. Cochrane Database Syst Rev. 2014;7:CD008207.
29. Warwick D, Harrison J, Whitehouse S, et al. A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. J Bone Joint Surg Br. 2002;84:344-350.
30. Blanchard J, Meuwly JY, Leyvraz PF, et al. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br. 199;81:654-659.
31. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antith-rombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;1:3791-3796106.
32. Salem M, Elrefai S, Shrit MA, et al. Fondaparinux thromboprophy-laxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thromb Haemost. 2010;104:1071-1072.
33. Greinacher A, Alban S, Omer-Adam MA, et al. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res. 2008;122:211-220.
34. Motokawa S, Torigoshi T, Maeda Y, et al. IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics. BMC Musculoskelet Disord. 2011;12:22.
35. Kreimann M, Brandt S, Krauel K, et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conforma-tional changes in platelet factor 4. Blood. 2014;124:2442-2449.
36. Brandt S, Krauel K, Gottschalk KE, et al. Characterisation of the con-formational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. Thromb Haemost. 2014;112: 53-64.
37. Migita K, Bito S, Nakamura M, et al. Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study. Arthritis Res Ther. 2014;16:R154.
38. Ho KM, Tan JA. Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation. 2013;128:1003-1020.
39. Matthews RAJ. Methods for assessing the credibility of clinical trial outcomes. Drug Inform J. 2001;35:1469-1478.